Search Results

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that it is initiating the company’s commercial footprint in its core focus area of cancer supportive care at the May 31 - June 4 American Society of Clinical Oncology (ASCO) Annual Meeting with a Napo Pharmaceuticals (Napo) exhibit booth for Gelclair®, the FDA-approved oral mucositis prescription product Jaguar in-licensed last month for the U.S. market.

Rapafusyn Pharmaceuticals is pleased to announce two upcoming presentations at Cambridge Health Institute’s 12th Annual Oral Peptides & Macrocyclics Conference, April 1 – 4 in San Diego.

ECRI, a global independent healthcare and patient safety nonprofit, names Clinica Imbanaco the winner of its 2024 Health Technology Excellence Award.

Boehringer Ingelheim announced that SENVELGO™, a revolutionary new treatment for cats with diabetes, has been approved by Health Canada, marking a significant step in the treatment of feline diabetes in Canada.

Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of proprietary oral formulations of Semaglutide (“Slim”) and Tirzepatide (“Trim”) to aid in weight management.

RevelAi Health and Zimmer Biomet Holdings, Inc., a global medical technology leader, announced a multi-year co-marketing agreement to commercialize generative artificial intelligence -powered engagement solutions that advance value-based orthopedic care and health equity.

Jaguar Health, Inc. today announced that the results of a third-party, investigator-initiated study of crofelemer, Napo’s novel plant-based prescription drug, show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and improved stool consistency in functional diarrhea patients.

Digital clinical diagnostics and diabetes home testing provider Digostics Limited announced a new commercial partnership with leading diabetes technology company, AgaMatrix Europe Limited, designed to accelerate the introduction of Digostics’ home oral glucose tolerance testing service, GTT@home, for gestational diabetes screening within the UK National Health Service.

Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities.

MIRA Pharmaceuticals, Inc. announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, towards clinical development for the treatment of severe post-traumatic stress disorder (PTSD) and other leading mental health disorders and neuropathic pain indications.